![](https://investorshub.advfn.com/uicon/604629.png?cb=1503346726)
Wednesday, June 06, 2018 12:46:47 PM
they would needed to have falsified a lot of data and research.
Sounds more a KTOV story to me here, than CYDY.
However, not closing a blind eye to negative statements,
would you be so kind and provide a little timetable plus some links for our own validation of Mr Burger's credibility?
That would be a good question to Mr Nader, if there is anything to it.
When did the fraud at Biocurex happen? More details please.
Still, I doubt all those papers & data of Pro140 for more than ten years are impacted in any way here.
Nonetheless will dig into Mr Burger's potential involvement - even if he was guilty, it must not mean that he falsified Pro140 data and papers being produced by others - sure not.
You might have noticed the April'18 CD01-Ext Monotrial paper, not even 'pumping' the result at all.
Too many are involved here.
+++
- Biocurex delisted 2013-2014?
- https://investorshub.advfn.com/BioCurex-Inc(fka-BOCX)-2475/
+++
Mr Burger
- https://www.bloomberg.com/research/stocks/private/person.asp?personId=362586&privcapId=10039157
-- Biocurex Executive Chairman: 2009-Present
-- CYDY 2014-present
CYDY Current Science Board https://www.cytodyn.com/media/press-releases/detail/273/cytodyn-forms-scientific-advisory-board-to-advance-pro-140
CYDY Current BOD https://www.cytodyn.com/about-cytodyn/board-of-directors
Mr Burger @ CYDY
Dr. Burger was appointed a Director in February 2014, named Vice Chairman in August 2014 and Chief Science Officer in January 2016. He is a life sciences executive with over 30 years of extensive scientific, operational and financial experience in the biotech industry. As CEO or chairman of several biotechnology companies, Dr. Burger has led numerous corporate financing transactions and public securities offerings and has experience leading R&D, GMP manufacturing and clinical development functional areas. Dr. Burger is currently a Director of Aptose Biosciences Inc., a cancer therapeutics, NASDAQ-listed company. Dr. Burger co-founded Trinity Biotech, a NASDAQ-listed diagnostic company, in June 1992, served as its Chairman from June 1992 to May 1995, and is currently lead independent director. Until March 2007, he was Chairman and Chief Executive Officer of AVI Biopharma Inc. (now Sarepta Therapeutics), a NASDAQ listed RNA therapeutics company. He was also a co-founder of Epitope Inc. (now Orasure Technologies, NASDAQ listed), serving as its Chairman from 1981 to 1990. Dr. Burger previously held a professorship in the Department of Microbiology and Immunology and Surgery (Surgical Oncology) at the Oregon Health and Sciences University in Portland. Dr. Burger received his undergraduate degree in Bacteriology and Immunology from the University of California in Berkeley and his Master of Science and Ph.D. degrees in Microbiology and Immunology from the University of Arizona.
Mr Burger @ Biocurex
Dr. Dennis Berger - Chairman of the Board
On September 8, 2009, the BioCurex Board of Directors elected Dr. Denis Burger to the executive office of Executive Chairman of the Company.
Prior to joining BioCurex, he had been Managing Director of Paradigm Ventures, LLC, a biotech investing and consulting firm, since 1991. He was
Chairman and CEO of AVI BioPharma, Inc., a drug development company using gene targeted therapeutics, from 1997 to 2007 and founding
Chairman of Epitope, Inc., a developer of diagnostic products from 1981 to 1990. He is currently a director of Trinity Biotech PLC, a diagnostic
products developer, and Lorus Therapeutics, a cancer therapeutics company.
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM